Literature DB >> 24183551

ACR appropriateness criteria staging and follow-up of ovarian cancer.

Donald G Mitchell1, Marcia C Javitt, Phyllis Glanc, Genevieve L Bennett, Douglas L Brown, Theodore Dubinsky, Mukesh G Harisinghani, Robert D Harris, Neil S Horowitz, Pari V Pandharipande, Harpreet K Pannu, Ann E Podrasky, Henry D Royal, Thomas D Shipp, Cary Lynn Siegel, Lynn Simpson, Jade J Wong-You-Cheong, Carolyn M Zelop.   

Abstract

Imaging is used to detect and characterize adnexal masses and to stage ovarian cancer both before and after initial treatment, although the role for imaging in screening for ovarian cancer has not been established. CT and MRI have been used to determine the resectability of tumors, the candidacy of patients for effective cytoreductive surgery, the need for postoperative chemotherapy if debulking is suboptimal, and the need for referral to a gynecologic oncologist. Radiographic studies such as contrast enema and urography have been replaced by CT and other cross-sectional imaging for staging ovarian cancer. Contrast-enhanced CT is the procedure of choice for preoperative staging of ovarian cancer. MRI without and with contrast may be useful after equivocal CT, but is usually not the best initial procedure for ovarian cancer staging. Fluorine-18-2-fluoro-2-deoxy-D-glucose-PET/CT may not be needed preoperatively, but its use is appropriate for detecting and defining post-treatment recurrence. Ultrasound is useful for evaluating adnexal disease, but has limited utility for staging ovarian cancer. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Copyright © 2013 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Appropriateness criteria; CT; FDG-PET; MRI; cancer staging; ovarian cancer

Mesh:

Year:  2013        PMID: 24183551     DOI: 10.1016/j.jacr.2013.07.017

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  11 in total

1.  Characterization of Adnexal Masses Using Contrast-Enhanced Subharmonic Imaging: A Pilot Study.

Authors:  Lauren J Delaney; Priscilla Machado; Mehnoosh Torkzaban; Andrej Lyshchik; Corinne E Wessner; Christine Kim; Norman Rosenblum; Scott Richard; Kirk Wallace; Flemming Forsberg
Journal:  J Ultrasound Med       Date:  2019-11-26       Impact factor: 2.153

Review 2.  An update on the role of PET/CT and PET/MRI in ovarian cancer.

Authors:  Benjapa Khiewvan; Drew A Torigian; Sahra Emamzadehfard; Koosha Paydary; Ali Salavati; Sina Houshmand; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-08       Impact factor: 9.236

3.  PET-detected asymptomatic recurrence is associated with improved survival in recurrent cervical cancer.

Authors:  Jocelyn S Chapman; I-Chow Hsu; Pamela N Peters; William E Pierson; Lee-May Chen; Antonio C Westphalen
Journal:  Abdom Radiol (NY)       Date:  2020-07-08

Review 4.  Revised FIGO staging system for cancer of the ovary, fallopian tube, and peritoneum: important implications for radiologists.

Authors:  Tsukasa Saida; Yumiko Oishi Tanaka; Koji Matsumoto; Toyomi Satoh; Hiroyuki Yoshikawa; Manabu Minami
Journal:  Jpn J Radiol       Date:  2015-12-22       Impact factor: 2.374

5.  Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study.

Authors:  Lino M Sawicki; Julian Kirchner; Johannes Grueneisen; Verena Ruhlmann; Bahriye Aktas; Benedikt M Schaarschmidt; Michael Forsting; Ken Herrmann; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-21       Impact factor: 9.236

6.  Simulated impact of pelvic MRI in treatment planning for pediatric adnexal masses.

Authors:  Alessandro Marro; Lisa M Allen; Sari L Kives; Rahim Moineddin; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2016-04-20

7.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

8.  A prognostic system for epithelial ovarian carcinomas using machine learning.

Authors:  Philip M Grimley; Zhenqiu Liu; Kathleen M Darcy; Matthew T Hueman; Huan Wang; Li Sheng; Donald E Henson; Dechang Chen
Journal:  Acta Obstet Gynecol Scand       Date:  2021-03-18       Impact factor: 4.544

9.  Formal consensus method to evaluate the conformity of prescription of a recently approved chemotherapy treatment in an observatory study.

Authors:  Nadine Houédé; Eric Leutenegger; Mariella Lomma; Carine Bellera
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

Review 10.  Evidence-Based Cancer Imaging.

Authors:  Atul B Shinagare; Ramin Khorasani
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.